News
2022
-
Group Company
Products
December 1, 2022
-
Launch of Nanozora® 30 mg Syringes for Subcutaneous Injection
-
Group Company
Corporate
November 24, 2022
-
Transfer and Future Marketing of Osteoporosis Agent Bonviva in Japan
-
Holdings
Investors
November 10, 2022
-
The 2nd Quarter of Fiscal 2022 Financial Statements
-
Holdings
Investors
November 10, 2022
-
Reference Data of The 2nd Quarter of Fiscal 2022 Financial Statements
-
Group Company
R&D
September 28, 2022
-
Notification of Application for Approval to Manufacture and Market Rheumatoid Arthritis Therapy Nanozora® 30mg Autoinjectors for S.C. Injection in Japan
-
Group Company
R&D
September 26, 2022
-
Notification of Approval to Manufacture and Market Nanozora® 30mg Syringes for S.C. Injection, a Therapy for Rheumatoid Arthritis, in Japan Japan's First NANOBODY® Therapeutic
-
Group Company
R&D
August 5, 2022
-
Cetylpyridinium chloride hydrate (CPC) confirmed to have an action of inactivating SARS-CoV-2 variants
-
Holdings
Investors
August 3, 2022
-
The 1st Quarter of Fiscal 2022 Financial Statements
-
Holdings
Investors
August 3, 2022
-
Reference Data of The 1st Quarter of Fiscal 2022 Financial Statements
-
Holdings
Investors
June 29, 2022
-
Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)
-
Holdings
Investors
May 13, 2022
-
Financial Statements for Fiscal 2021
-
Holdings
Investors
May 13, 2022
-
Reference Data of Financial Statements for Fiscal 2021
-
Group Company
Corporate
April 14, 2022
-
Former All Blacks players Richard McCaw and Daniel Carter appointed Lipovitan Ambassadors
-
Holdings
Investors
February 1, 2022
-
The 3rd Quarter of Fiscal 2021 Financial Statements
-
Holdings
Investors
February 1, 2022
-
Reference Data of The 3rd Quarter of Fiscal 2021 Financial Statements